Chao Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chao Huang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Guosong Jiang
Department of Urology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
17 shared publications - Hui Zhang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 shared publications - Xincheng Gao
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 shared publications - Huayuan Zhao
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Jiayin Sun
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 shared publications - Junping Li
Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, China
14 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer
MSH2 (mutS homolog 2) gene, a key component of the DNA mismatch repair system, garners significant attention for its influence on cancer progression and prognosis. Loss of MSH2 protein decreases the chemosensitivity of bladder cancer (BCa) to cisplatin (CDDP). However, precision therapeutic strategy based on MSH2 deficiency is not available clinically. Herein, we reported that knockout of MSH2 reduced the sensitivity of BCa to CDDP. Importantly, GK921, a TGM2-specific inhibitor, increased tumor cell killing by CDDP in MSH2-deficient BCa. GK921 also promoted the chemotherapeutic sensitivity of Msh2-knockout mice to CDDP. In addition, Hi-C analysis indicated that MSH2 deficiency rewired chromatin accessibility of the TGM2 promoter region, leading to recruit more transcription factors. Accordingly, we found that the enrichment levels of transcription factor AP-1 in TGM2 promoter region were increased in MSH2-knockout BCa cells, thereby promoting the expression of TGM2 transcriptionally. This study uncovers that CDDP effectiveness depends on TGM2 levels in MSH2-deficient BCa and that the combination of CDDP with TGM2 inhibition may represent a promising therapeutic strategy for MSH2-deficient BCa patients.
- 28 May 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessInhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer
MSH2 (mutS homolog 2) gene, a key component of the DNA mismatch repair system, garners significant attention for its influence on cancer progression and prognosis. Loss of MSH2 protein decreases the chemosensitivity of bladder cancer (BCa) to cisplatin (CDDP). However, precision therapeutic strategy based on MSH2 deficiency is not available clinically. Herein, we reported that knockout of MSH2 reduced the sensitivity of BCa to CDDP. Importantly, GK921, a TGM2-specific inhibitor, increased tumor cell killing by CDDP in MSH2-deficient BCa. GK921 also promoted the chemotherapeutic sensitivity of Msh2-knockout mice to CDDP. In addition, Hi-C analysis indicated that MSH2 deficiency rewired chromatin accessibility of the TGM2 promoter region, leading to recruit more transcription factors. Accordingly, we found that the enrichment levels of transcription factor AP-1 in TGM2 promoter region were increased in MSH2-knockout BCa cells, thereby promoting the expression of TGM2 transcriptionally. This study uncovers that CDDP effectiveness depends on TGM2 levels in MSH2-deficient BCa and that the combination of CDDP with TGM2 inhibition may represent a promising therapeutic strategy for MSH2-deficient BCa patients.
- Open Access
- 9 February 2026
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 24 (2) , e3003647
CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy
CD8 + T cells are capable of specifically targeting and eliminating malignant tumor cells, but tumor cells can develop resistance mechanisms to escape CD8 + T cell-mediated killing. Here, we performed a whole genome CRISPR-Cas9 knockout screen under CD8 + T cells pressure and identified the E3 ubiquitin ligase CUL5 as an essential factor required for escaping CD8 + T cells killing in bladder cancer cells. We found that CUL5 knockout promoted the sensitivity of bladder cancer cells to CD8 + T cell-mediated killing both in vivo and in vitro. Mechanistically, CUL5 loss reduced the ubiquitination of PTBP1, which regulated alternative splicing of RUBCN pre-mRNA and led to an increase in the levels of the RUBCN-S isoform, thereby preventing immune evasion of bladder cancer cells by inhibiting autophagy. Importantly, CUL5 knockout significantly enhanced the efficacy of anti-PD-1 immunotherapy in a xenograft model. Collectively, these findings reveal a novel mechanism of bladder cancer immune evasion, providing potential targets for cancer immunotherapy.
- 9 February 2026
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 24 (2) , e3003647
Open AccessCUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy
CD8 + T cells are capable of specifically targeting and eliminating malignant tumor cells, but tumor cells can develop resistance mechanisms to escape CD8 + T cell-mediated killing. Here, we performed a whole genome CRISPR-Cas9 knockout screen under CD8 + T cells pressure and identified the E3 ubiquitin ligase CUL5 as an essential factor required for escaping CD8 + T cells killing in bladder cancer cells. We found that CUL5 knockout promoted the sensitivity of bladder cancer cells to CD8 + T cell-mediated killing both in vivo and in vitro. Mechanistically, CUL5 loss reduced the ubiquitination of PTBP1, which regulated alternative splicing of RUBCN pre-mRNA and led to an increase in the levels of the RUBCN-S isoform, thereby preventing immune evasion of bladder cancer cells by inhibiting autophagy. Importantly, CUL5 knockout significantly enhanced the efficacy of anti-PD-1 immunotherapy in a xenograft model. Collectively, these findings reveal a novel mechanism of bladder cancer immune evasion, providing potential targets for cancer immunotherapy.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Effects of DMSO, MCHA, Erdafitinib and combined treatment on the indicators of cardiac, hepatic, and renal function of mice.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Effects of DMSO, MCHA, Erdafitinib and combined treatment on the indicators of cardiac, hepatic, and renal function of mice.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementay Table 1 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of primers used in this study.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementay Table 1 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of primers used in this study.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S5 shows that HMGA2 directly binds to the promoter of EGFR.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S5 shows that HMGA2 directly binds to the promoter of EGFR.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Determination of the protein potentially regulated by SRM using Venn analysis.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Determination of the protein potentially regulated by SRM using Venn analysis.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S7 shows that SRM inhibitor MCHA is synthetic lethal with Erdafitinib.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S7 shows that SRM inhibitor MCHA is synthetic lethal with Erdafitinib.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S2 shows that SRM loss enhances erdafitinib efficacy in bladder cancer.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S2 shows that SRM loss enhances erdafitinib efficacy in bladder cancer.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S4 shows that SRM supports the efficient translation of HMGA2 by eIF5A hypusination.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Figure. S4 shows that SRM supports the efficient translation of HMGA2 by eIF5A hypusination.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementay Table 2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of shRNA and sgRNA used in this study.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementay Table 2 from A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
The sequences of shRNA and sgRNA used in this study.